CTLA4 and hypophysitis: The frequency of hypophysitis is higher in patients treated with monoclonal antibodies against CTLA-4 (1–18%) [99,100,101,102,103] than those treated with PD-1 inhibitors (0.5–1.5%) [103,104,105].